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Abstract: Upon inflammation, monocyte-derived macrophages (MΦ) infiltrate blood vessels to
regulate several processes involved in vascular pathophysiology. However, little is known about
the mediators involved. Macrophage polarization is crucial for a fast and efficient initial response
(GM-MΦ) and a good resolution (M-MΦ) of the inflammatory process. The functional activity of
polarized MΦ is exerted mainly through their secretome, which can target other cell types, including
endothelial cells. Endoglin (CD105) is a cell surface receptor expressed by endothelial cells and MΦ
that is markedly upregulated in inflammation and critically involved in angiogenesis. In addition, a
soluble form of endoglin with anti-angiogenic activity has been described in inflammation-associated
pathologies. The aim of this work was to identify components of the MΦ secretome involved in
the shedding of soluble endoglin. We find that the GM-MΦ secretome contains metalloprotease 12
(MMP-12), a GM-MΦ specific marker that may account for the anti-angiogenic activity of the GM-MΦ
secretome. Cell surface endoglin is present in both GM-MΦ and M-MΦ, but soluble endoglin is
only detected in GM-MΦ culture supernatants. Moreover, MMP-12 is responsible for the shedding
of soluble endoglin in vitro and in vivo by targeting membrane-bound endoglin in both MΦ and
endothelial cells. These data demonstrate a direct correlation between GM-MΦ polarization, MMP-12,
and soluble endoglin expression and function. By targeting endothelial cells, MMP-12 may represent
a novel mediator involved in vascular homeostasis.
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1. Introduction
Inflammation is an adaptive response that is triggered by noxious stimuli and conditions, such as
infection and tissue injury [1]. Macrophages (MΦ) are critically involved in host defense by regulating
inflammatory responses, as well as tissue remodeling, repair, and healing [2]. In inflammation-related
cardiovascular disease, MΦ represent a major component of vessel wall infiltrates where they display
great plasticity regulating a variety of pathophysiological processes [3,4], including atherosclerosis,
myocardial infarction, atrial fibrilation, stroke, homeostatic arterial remodeling, hypertension,
angiogenesis, or vasculitides [5–9]. It is widely accepted that the recruitment of MΦ to vascular
inflammatory lesions involve the transit of circulatory monocytes through the vascular endothelium,
a process associated with their activation/differentiation to MΦ [5,10,11]. This migration of monocytes
involves adhesive interaction of their cell surface integrins with receptors expressed on endothelial
cells [12–14]. Once differentiated, MΦ release inflammatory mediators that regulate vascular function
in a process that is poorly understood.
An adequate regulation of macrophage polarization is crucial for a fast and efficient initial response
(pro-inflammatory GM-MΦ) and a good resolution (anti-inflammatory M-MΦ) of the inflammatory
process. Human MΦ are classified according to the activation stimuli into, at least, two polarization
states based on their profiles of secreted proteins, including cytokines and matrix metalloproteinases
(MMPs) [15]. Thus, MΦ generated in the presence of GM-CSF or M-CSF are representative of the
pro-inflammatory (GM-MΦ) or the anti-inflammatory (M-MΦ) polarization states, respectively [16,17].
Among MΦ-secreted proteins, MMPs are a family of proteases that contain a zinc atom at their active
site and are able to regulate endothelial sprouting and angiogenesis by degrading different extracellular
matrix proteins, including collagen, laminin, and elastin [18,19]. Human elastase, also known as
MMP-12, was first identified as an elastolytic metalloproteinase secreted by inflammatory alveolar
MΦ [20]. MMP-12 is considered not only as a GM-MΦ pro-inflammatory marker [21,22] but also
as a pro-inflammatory protease whose expression is induced by the cytokine GM-CSF [23,24]. The
presence of MMP-12 has been reported in inflammation-associated atherosclerosis [25,26] and other
vascular pathologies like aortic dissection, retinopathy, intracerebral hemorrhage, peripheral vascular
damage, arterial stiffening, obstructive pulmonary disease (COPD), or deep vein thrombosis [27].
Moreover, the atherosclerotic plaque MMP-12-positive MΦ subset predicts adverse outcomes after
endarterectomy [28], while MMP-12 inhibition retards atherosclerotic plaque development in a mouse
model [29]. Furthermore, MMP-12 inhibits wound healing and endothelial-driven angiogenesis in vitro
and in vivo while promoting endothelial cell apoptosis [30–34]. In spite of the functional effects of
MMP-12 on the vascular endothelia, many of its target endothelial proteins remain to be identified.
Endoglin (CD105) is a membrane glycoprotein that is highly expressed in endothelial cells [35] and
at lower levels in MΦ [36,37]. It is an auxiliary receptor for the members of the transforming growth
factor-β (TGF-β) family, and a role for endothelial endoglin in pathological conditions involving the
vasculature, including hereditary hemorrhagic telangiectasia type 1 (HHT1), preeclampsia, and cancer
angiogenesis, has been described [38–41]. Endoglin expression in endothelia is strongly upregulated
and is consistently associated with an infiltrate of inflammatory cells during inflammation and dermal
wound healing in vivo [42]. In this context, a regulatory role for endoglin in transendothelial monocyte
trafficking has been suggested, by which endothelial endoglin interacts with monocyte integrins,
and this cell-cell adhesion process is stimulated by inflammatory stimuli [13]. In addition to the
membrane-bound protein, high levels of circulating endoglin (soluble endoglin; sEng) in plasma from
patients with preeclampsia, cancer, or inflammatory-related diseases such as atherosclerosis, psoriasis,
or rheumatoid arthritis, has been reported [40,41,43–47]. Shedding of the ectodomain of endoglin can
be triggered by inflammation, tumor necrosis factor α (TNF-α), endothelial injury, or anti-endoglin
antibodies [47–51]. Of note, sEng (i) displays pro-inflammatory activity via nuclear factor-kappa B
(NFκB) and interleukin 6 (IL6) in human endothelial cells [52]; (ii) shows antiangiogenic activity and
increased vascular permeability in vitro and in vivo [40,51,53]; (iii) modulates inflammation-associated
monocyte adhesion and transmigration [13]; (iv) contributes to endothelial dysfunction, as shown
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in transgenic animals overexpressing human sEng [54,55]; and (v) regulates vascular development
and arteriovenous malformations by modulating angiogenesis [47]. Therefore, identification of the
mechanisms responsible for the generation of sEng in the inflammatory context may provide novel
therapeutic targets for inflammation-related vascular pathologies. Here, we provide evidence that the
metalloelastase MMP-12 is the major MΦ protease that targets membrane-bound endoglin in MΦ and
endothelial cells, leading to the shedding of soluble endoglin in inflammatory associated processes,
and so the consideration of both MMP-12 and soluble endoglin as correlated GM-MΦ polarization
markers. This is the first time that the human GM-MΦ/MMP-12/soluble endoglin axis is functionally
reported in an inflammatory context.
2. Results
2.1. Inhibitory Effect of the GM-MΦ Secretome on Endothelial Tubulogenesis
Human monocytes were cultured for six days in the presence of GM-CSF (GM-MΦ) or M-CSF
(M-MΦ), and culture supernatants were collected. Then, the effect of these supernatants on endothelial
tubulogenesis, a crucial step in the formation of functional blood vessels during angiogenesis, was
tested. As shown in Figure 1, culture supernatants from GM-MΦ, but not from M-MΦ, significantly
decreased endothelial tubulogenesis at two different times points (3 h and 6 h), and this effect was
confirmed with MΦ derived from at least five different donors. In addition, wound healing experiments
(n = 4) in human endothelial monolayers showed that culture supernatants from GM-MΦ (27.21% +/−
1.28 wound closure vs. 42.84% +/− 12.4 of control; p = 0.048), but not from M-MΦ (44.57% +/− 4.70; no
significant difference vs. control), significantly decreased endothelial cell migration at 8 h post-wound.
These results suggest that the GM-MΦ secretome exerts an anti-angiogenic activity on endothelial cells.
In order to identify the specific component of the GM-MΦ secretome involved in this inhibitory
activity, we next analyzed the relative expression profile of different MMPs in GM-MΦ and M-MΦ by
qRT-PCR. Of note, the family of MMPs has been shown to regulate vascular endothelial function [18,19].
As shown in Figure 2A, the metalloelastase MMP-12 displayed the highest GM-MΦ/M-MΦ ratio
among 12 different MMPs analyzed. In addition, most of the MMPs, except MMP-7, showed relatively
low expression levels in GM-MΦ compared to M-MΦ. A kinetic study showed a marked differential
expression of the MΦ MMP-12 mRNA, as it was expressed at much higher levels in pro-inflammatory
GM-MΦ than in M-MΦ (Figure 2B,C), which is in line with a previous report [21]. This differential
expression of MMP-12 was seen at all time points during MΦ differentiation, which is in agreement
with the reported effects of GM-CSF on GM-MΦ [23,24]. As a control, the kinetic expression levels of
MMP-14 showed similar expression levels in GM-MΦ and M-MΦ during all time points (Figure 2B). The
differential upregulated expression of MMP-12 in GM-MΦ versus M-MΦwas also demonstrated at the
protein level by ELISA (Figure 2D), and its biological significance was corroborated by a zymography
assay on casein. As shown in Figure 2E, GM-MΦ supernatants exhibited a higher MMP-12-specific
peptidase activity as compared to M-MΦ supernatants. As a control, the activity of the secreted
MMP-12 from transfected COS-7 cells was also evident (Figure 2E). In fact, the digestion pattern
observed in MMP-12 transfectants was similar to that obtained using GM-MΦ supernatants, with the
appearance of two specific bands around 100- and 30-kDa. Conversely, no specific digestion bands
were observed in supernatants from either M-MΦ or mock-transfected COS-7 cells.
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Figure 1. Effect of GM-MΦ and M-MΦ supernatants on tubulogenesis. Matrigel was mixed (at 1:1 
dilution) with control medium or macrophage (MΦ) supernatants from three different donors (#18, 
#19, and #20), and the mixture was added to plates and incubated for 1 h. Then, human umbilical 
vein-derived endothelial cells (HUVECs) in vascular endothelial growth factor (VEGF)-enriched 
EBM2/EGM2 medium were added to Matrigel plates and incubated for the times indicated at 37 °C. 
The cord network formation was visualized by taking pictures at 3 h and 6 h after cell plating and 
representative images are shown (A). The appearance of an almost complete network is achieved by 
6 h in cells incubated with control medium or cells treated with M-MΦ supernatants; while in the 
presence of GM-MΦ supernatants, open tubules with some patches of disorganized and sparse cells 
are observed. Scale bar: 100 μm. The number of closed tubes in the network was quantified and 
representative assays of more than three different experiments per condition are shown (B). The 
Figure 1. Effect of GM-MΦ and M-MΦ supernatants on tubulogenesis. Matrigel was mixed (at 1:1
dilution) with control medium or macrophage (MΦ) supernatants from three different donors (#18,
#19, and #20), and the mixture was added to plates and incubated for 1 h. Then, human umbilical
vein-derived endothelial cells (HUVECs) in vasc l r endothelial growth factor (VEGF)-enriched
EBM2/EGM2 medium were added to Matrigel s and incubated for the times indicated at 37 ◦C.
The cord network formation was visualized i g pictures at 3 h and 6 h aft r cell plati g and
representative images are shown (A). The appearance of an almost complete network is achieved by
6 h in cells incubated with control medium or cells treated with M-MΦ supernatants; while in the
presence of GM-MΦ supernatants, open tubules with some patches of disorganized and sparse cells
are observed. Scale bar: 100 µm. The number of closed tubes in the network was quantified and
representative assays of more than three different experiments per condition are shown (B). The mean
number of closed tubes, representing all the experiments (n = 6), is shown by histograms (C). Statistical
significance was calculated with one way ANOVA and data are presented as mean ± SEM. (*p < 0.05;
**p < 0.01; ***p < 0.001).
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Figure 2. Expression profile of matrix metalloproteinases (MMPs) in GM-MΦ and M-MΦ. Human 
monocytes were incubated with GM-CSF or M-CSF, resulting in GM-MΦ and M-MΦ, respectively. 
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Figure 2. Expression profile of matrix metalloproteinases (MMPs) in GM-MΦ and M-MΦ. Human
monocytes were incubated with GM-CSF or M-CSF, resulting in GM-MΦ and M-MΦ, respectively.
(A) The relative mRNA expression levels of different MMPs was determined by qRT-PCR and
represented by the GM-MΦ/M-MΦ ratio. (B) mRNA expression levels of MMP-12 and MMP-14
along GM-MΦ and M-MΦ polarization, as determined by qRT-PCR. The statistical significance of
GM-MΦ versus M-MΦ data is shown. (C) MMP-12 mRNA expression of GM-MΦ and M-MΦ analyzed
by RT-PCR, followed by agarose gel analysis of the product. (D) MMP-12 protein levels in culture
supernatants at the final stage of differentiation were measured by ELISA. (E) Caseinolytic zymography
assay of culture supernatants of GM-MΦ and M-MΦ (left panel), and COS-7 cells transfected with or
without an expression vector encoding MMP-12 (right panel). A control of RMPI medium with or
without fetal bovine serum (FBS) was included in the left panel. The caseinolytic activity was revealed
by the white staining over the blue background of total proteins stained with Coomassie Brilliant Blue.
Statistical analysis of triplicates was calculated using the paired two-tailed Student t test and data are
presented as mean ± SD. (*p < 0.05; **p < 0.01; ***p < 0.001).
These results suggest that, among the MMP family, MMP-12 is a major component of the GM-MΦ
secretome. Because MMP-12 has been associated with anti-angiogenic activity [30–34], we tested the
possibility that MMP-12 was involved in the tubulogenesis inhibition induced by GM-MΦ supernatants.
Supporting this hypothesis, we found that the MMP-12 inhibitor MMP-408 [56] significantly rescued
the GM-MΦ supernatant-induced inhibition of endothelial tubulogenesis (Figure 3). These data suggest
that MMP-12 is involved in the tubulogenesis inhibition induced by GM-MΦ supernatants.
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Figure 3. Effect of GM-MΦ supernatants on endothelial tubulogenesis in the presence of the MMP-12 
inhibitor. HUVECs were incubated on Matrigel plates, as described in Figure 1, but in the absence (−) 
or presence (+Inh) of the MMP-12 inhibitor MMP-408, as indicated. Addition of MMP-408 
Figure 3. Effect of GM-MΦ supernatants on endothelial tubulogenesis in the presence of the MMP-12
inhibitor. HUVECs were incubated on Matrigel plates, as described in Figure 1, but in the absence (−)
or presence (+Inh) of the MMP-12 inhibitor MMP-408, as indicated. Addition of MMP-408 significantly
rescued the tubulogenesis inhibition induced by GM-MΦ supernatants. The cord network formation
was visualized, and representative assays of more than three different experiments per condition (n = 6)
are shown (A). Scale bar: 100 µm. The number of closed tubes in the network was quantified and
represented by histograms (B). Statistical significance was calculated using one way ANOVA, and data
are presented as mean ± SEM. (*p < 0.05; ***p < 0.001).
2.2. Expression of Endoglin in Monocyte-Derived MΦ
Because MMP-12 exerts its proteolytic activity on a variety of protein substrates, we searched for
potential target proteins that could account for its anti-angiogenic function. Interestingly, we found
that endoglin, a membrane protein present in MΦ, can be cleaved, at least, by MMP-14, generating a
soluble form of endoglin with anti-angiogenic properties [40,51,53]. As MMP-14 is expressed at much
lower levels than MMP-12 in GM-MΦ (Figure 2A) and no relevant differences were found between
GM-MΦ and M-MΦ with respect to the transcript levels of MMP-14 (Figure 2B), we then focused on
the potential targeting of endoglin by MMP-12. Human monocytes obtained from healthy donors and
polarized in vitro showed different endoglin levels in their culture supernatant at the final stage of
differentiation (Figure 4A). GM-CSF-polarized GM-MΦ presented levels of sEng up to 400 pg/mL,
whereas M-CSF-polarized M-MΦ did not show detectable levels of sEng.
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Figure 4. Endoglin expression in GM-MΦ and M-MΦ. Human monocytes were incubated with
GM-CSF or M-CSF, resulting in GM-MΦ and M-MΦ, respectively. Soluble endoglin (sEng) levels were
measured by ELISA in culture supernatants at the final stage of differentiation (A) or during a kinetic
study (B). In panel B, the statistical significance with respect to the control sample (day 0) is indicated.
(C) Comparative mRNA expression levels of endoglin along GM-MΦ and M-MΦ polarization, as
determined by qRT-PCR. (D) Endoglin protein levels at the surface of GM-MΦ and M-MΦ were
detected by immunofluorescence flow cytometry using a ouse monoclonal antibody directed against
human endoglin. Values of mean fluorescence intensity (MFI) are indicated. Statistical analysis was
calculated using the paired two-tailed Student t test (n = 3), and ata are presented as mean ± SD.
(* < 0.05; **p < 0.01).
A kinetic study showed that this effect was accu ulati e a eas ra le ri t e onocyte to
MΦ transition, and the diff renc be am significa t 24 h after monocyte exposure to each cytokine
(Figure 4B). By contrast, the level of sEng released from non-stimulated monocytes were usually below
detection range. Th prefe e tial pr sence of sEng in GM-MΦ supernatants agrees with the increased
levels of sEng previously found in inflammatory-related pathologies [40,41,43,45–47]. Importantly,
the differences in sEng levels between both MΦ subsets did not reflect parallel mRNA levels of
endoglin (ENG), which were roughly similar between GM-MΦ and M-MΦ all along the differentiation
process (Figure 4C). Moreover, significant differences were observed in the cell surface expression
levels of endoglin in both MΦ subtypes (Figure 4D). Actually, there was a lower level of surface
endoglin in GM-MΦ versus M-MΦ, a finding compatible with an active release of sEng in the GM-MΦ
subset. Overall, these results are in line with the hypothesis that membrane endoglin is a target of
GM-MΦ MMP-12.
2.3. Endoglin Shedding from GM-MΦ Cell Surface is Mediated by MMP-12
The above hypothesis prompted us to analyze whether sEng was shed from the cell surface
via the proteolytic activity of MMP-12 (Figure 5). The presence of the MMP-12-specific inhibitor
MMP-408 during GM-CSF-driven polarization significantly reduced the concentration of sEng in
GM-MΦ-conditioned medium, whereas the levels of sEng in M-MΦ supernatants remained low and
unchanged (Figure 5A). In addition, transfection with siRNA directed to MMP-12 led to the down
regulation of MMP-12 at the mRNA (Figure 5B) and protein (Figure 5C) level, and resulted in a
significantly decreased secretion of sEng by GM-MΦ (Figure 5D). As another means to assess the ability
of MMP-12 to shed endoglin from the cell surface, both MMP-12 and endoglin were over-expressed in
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COS-7 cells, which are devoid of endoglin and MMP-12 (Figure 5E). Co-transfection of both endoglin
and MMP-12 resulted in a significant increase in the level of sEng compared to cells lacking MMP-12
expression (Figure 5F). These results suggest that the protease activity of MMP-12 is responsible for the
presence of sEng shed by GM-MΦ.
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Figure 5. Expression of MΦ soluble endoglin induced by MMP-12. (A) Effect of the MMP-12 specific
inhibitor MMP-408 on the release of soluble endoglin during in vitro macrophage polarization of
human monocytes. (B–D) Effect of MMP-12 silencing in GM-MΦ. GM-MΦ were transfected with
siRNA targeting MMP-12 or negative control (siC). After 48 h, MMP-12 mRNA (B) and protein (C)
levels were determined by qRT-PCR and ELISA, respectively. Soluble endoglin levels were also
measured in GM-MΦ culture supernatants (D). (E,F) Recombinant expression of MMP-12 releases
soluble endoglin from membrane bound endoglin. COS-7 cells were co-transfected with endoglin (ENG),
GFP, and MMP-12, as indicated. Transfection efficiency was visualized by fluorescence microscopy
of GFP-expressing cells (E, upper panel) and by Western blot analysis (E, lower panel). A negative
control with an empty vector (Φ) is included. Soluble endoglin levels were measured by ELISA in
culture supernatants from transfected COS-7 cells. Statistical analysis was calculated using the paired
two-tailed Student t test (n = 4), and data are presented as mean ± SD. (*p < 0.05; **p < 0.01).
2.4. MMP-12 Induces Soluble Endoglin Release in Endothelial Cells
Next, we sought to determine whether GM-MΦ-derived MMP-12 can also act on endothelial cells,
which constitute the major source of endoglin. To that end, primary cultures of HUVECs were exposed
to GM-MΦ- or M-MΦ-conditioned media (Figure 6A). As shown in Figure 6B, the GM-MΦ-conditioned
medium triggered a significantly higher level of HUVEC-derived sEng, as compared to the M-MΦ
medium. Of note, the levels of sEng in MΦ-supernatants were much lower than those obtained after
incubation with HUVECs (Figure 6B).
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Figure 6. Secretion of endothelial soluble endoglin induced by MΦ supernatants. (A–D) As indicated
in the scheme (A), culture supernatants (SUP) from GM-MΦ (GM) or M-MΦ (M) were added to
monolayers of HUVECs. After 24 h incubation, the culture media were collected, and the sEng content
was measured by ELISA in all samples. The values of sEng were calculated after subtracting the
basal release of sEng present in HUVECs supernatants (B–D). (B) The levels of sEng from GM-MΦ
and M-MΦ supernatants (left two bars) are compared to those after incubation with HUVECs (right
two bars). (C) Soluble endoglin levels from GM-MΦ and M-MΦ supernatants after incubation with
HUVECs in the presence or absence of MMP-408. (D) Soluble endoglin levels from supernatants of
GM-MΦ, previously transfected with siRNA-MMP-12 or -control (siC), after incubation with HUVECs.
(E) Effect of endoglin peptides (P230, P583, P447) and the specific inhibitor MMP-408 on the proteolytic
activity of recombinant human MMP-12. Control samples with vehicle (CTL), the GL-less peptide P230,
as well as an inactive MMP-12, are included. The MMP-12 activity was measured using the fluorogenic
substrate Mca-PLGL-Dpa-ARNH2, and the statistical significance respect to the control sample (CTL)
is indicated. Statistical analysis (n = 3) was calculated using the ANOVA test, and data are presented as
mean ± SD. (*p < 0.05; **p < 0.01; ***p < 0.001).
The involvement of MMP-12 in the endothelial shedding of sEng was then assessed. First, the
levels of endothelial sEng induced by the GM-MΦ-conditioned medium were inhibited in the presence
of the MMP-12 inhibitor MMP-408 (Figure 6C). Next, a significantly decreased expression of sEng
was detected in HUVECs exposed to supernatants from GM-MΦ transfected with siRNA-MMP-12
(Figure 6D). Furthermore, the ability of MMP-12 to target the endoglin sequence was evaluated using an
in vitro assay with recombinant MMP-12 and an MMP-12-sensitive fluorogenic peptide. As expected,
the MMP-12 specific inhibitor MMP-408 [56] decreased the proteolytic activity of MMP-12 by 80%
(Figure 6E). Interestingly, a significant inhibition of MMP-12 activity on the fluorogenic peptide was also
observed in the presence of endoglin-specific peptides P583 and P447, where both of them include the
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consensus Gly-Leu (GL) recognition sequence for MMPs, which is in agreement with their inhibitory
effect against MMP-14 activity on endothelial endoglin [57]. As a negative control, the GL-less peptide
P230 had no effect on the proteolytic activity of MMP-12. Overall, these data suggest that MMP-12 is
capable of proteolytically targets membrane-bound endoglin in endothelial cells.
2.5. MMP-12 Induces Soluble Endoglin Release in an in Vivo Mouse Model of Inflammation
As a means to address the physiological relevance of the MMP-12-dependent sEng release, we
initially analyzed the expression of MMP-12 in murine bone marrow-derived GM-MΦ and M-MΦ.
GM-CSF-driven polarization resulted in higher levels of Mmp-12 mRNA than in M-CSF-treated
macrophages (Figure 7A), which is in agreement with findings from human polarized MΦ (Figure 2).
Based on this result, we undertook the analysis of the levels of circulating sEng in response to
lipopolysaccharide (LPS), a powerful stimulus of acute inflammatory responses. The i.p. injection of
LPS and the non-lethal associated inflammatory response resulted in a significant increase of sEng
levels in the plasma after 48 h (Figure 7B), indicating that the release of sEng is also a marker for the
LPS-induced in vivo inflammatory response. Importantly, the LPS-induced increase in plasma sEng
was significantly abolished by the MMP-12 inhibitor MMP-408, whose only presence had no effect
on the basal levels of sEng in plasma (Figure 7B). Together, these results suggest that MMP-12 is also
involved in the release of sEng in an in vivo inflammatory mouse model.
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Figure 7. MMP-12-dependent release of soluble endoglin in mice. (A) Transcript expression levels of
Mmp-12 in ri e e arr - eri ed Φ incubated with GM-CSF (GM-MΦ) or M-CSF (M-MΦ), as
determined by qRT-PCR. Statistical significa ce of data (n = 4) was calculated using a paired, two-tailed
Student t test, and data are presented as mean ± SD. (B) Soluble endoglin levels in lipopolysaccharide
(LPS)-tre ted nimals. Mice w re i jected (i.p.) ith LPS an orally gavaged with MMP-408 or vehicle
(PBS). Plasma samples were extracted, and soluble endoglin was measured usi g an ELISA kit. A point
cloud representat on is shown where blue horiz tal bars i dicate the median values of each condi ion.
Statistical significance was calculated (n ≥ 5) using the ANOVA test, and data are presented as mean
± SD.
3. Discussion
Macrophages regulate a variety of processes involving vascular inflammation. There is a wide
range of vascular inflammatory diseases, including atherosclerosis, hypertension, vasculitides aortic
aneurism, or rare vascular syndromes [3,7,58]. Together, these are widespread conditions that affect a
large population worldwide, sometimes leading to fast and irreversible organ failure. Polarization
and accumulation of MΦ upon chronic pro-inflammatory signals may result in extensive vascular
damage, adverse repair, and worsened clinical outcomes [59]. Therefore, targeting the inflammatory
MΦ activation may lead to an early resolution of inflammation with potential therapeutic benefits.
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Unfortunately, how MΦ regulate the inflammatory responses in the vasculature is poorly understood.
In this context, elucidating novel mechanisms of MΦ polarization may lead to a better understanding of
their roles in vascular inflammation. In this manuscript, we report a new link between pro-inflammatory
GM-MΦ and endothelial cells, by which GM-MΦ-derived MMP-12 targets membrane bound endothelial
endoglin, leading to the release of sEng, a soluble protein with pro-inflammatory properties and the
potential to promote endothelial dysfunction in combination with hypercholesterolemia [55]. Our
results suggest that there is a direct and synergic effect of both MMP-12 and sEng in the context of
the GM-MΦ/pro-inflammatory macrophage response (Figure 8). Supporting this view, it has been
reported that in inflammation-associated pathologies in which MMP-12 levels are increased [26,29,60],
there is also an augmented level of sEng [44,61–63]. Furthermore, we found that GM-MΦ supernatants
show an MMP-12-dependent inhibitory activity on endothelial tubulogenesis, which is in agreement
with the reported anti-angiogenic effect of both sEng [40,47,53] and MMP-12 [30–33].
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Figure 8. Hypothetical odel for P-12 in sEng secretion and endothelial function. Circulating
monocytes ( o) can be polarized in the presence of G -CSF or -CSF, leading to pro-inflammatory
GM-MΦ or anti-inflammatory M-MΦ, respectively. GM-MΦ, but not M-MΦ, secrete high levels
of MMP-12, which in turn triggers the release of sEng in GM-MΦ and endothelial cells (ECs) by
proteolytically cleaving membrane-bound endoglin. The effects of sEng include inhibition of tube
formation and a pro-inflammatory stimulus on ECs that may lead to endothelial dysfunction.
These data suggest that both soluble proteins act in concert, contributing to the progression of
the GM-MΦ response in both physiological and pathological processes. In this line, several lines
of evidence support the functional relationship between MΦ and endoglin. Thus, MΦ endoglin
knockout mice show a predisposition to develop spontaneous infections by opportunistic bacteria,
increased survival following LPS-induced peritonitis, and impaired phagocytic activity in endoglin
deficient peritoneal MΦ [64]. Interestingly, this altered function of endoglin-deficient MΦ could help
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to explain the higher rate of infectious diseases seen in patients with HHT1, a vascular disease caused
by heterozygous mutations in the endoglin gene [65,66]. This is also in agreement with the impaired
resolution of inflammation reported in an endoglin heterozygous HHT1 mouse model of chronic
colitis [67]. In addition, endothelial endoglin can regulate integrin-dependent monocyte adhesion and
extravasation upon inflammatory stimuli, and these processes can also be modulated by sEng [13]. As
the inflammatory infiltrate of MΦ plays a critical role in vascular remodeling [58] and such infiltrate
has been reported in vascular lesions of HHT1, a pathogenic role for the impaired monocyte/MΦ
infiltration in this disease has been postulated [38,68,69].
Macrophages are critical components in inflammatory diseases that occur within and around blood
vessels and lead to severe vascular damage and tissue ischemia. Integrating the new findings reported
here can unravel novel therapeutic targets through better understanding of the pro-inflammatory
crosstalk between MΦ and the endothelium. In the context of chronic inflammation in the vascular
disease, studies on MΦ and endothelial biology are key to harnessing inflammation.
4. Materials and Methods
4.1. Macrophage Culture and Differentiation
All cells were incubated routinely at 37 ◦C in a humidified atmosphere with 5% CO2. This study
was approved by the Centro de Investigaciones Biológicas Ethics Committee, and all experiments were
carried out in accordance with institutional guidelines and regulations. Blood-derived buffy coats of
normal donors were anonymously provided by the Comunidad Autonoma de Madrid Blood Bank.
Human peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats over a Lymphoprep
(Nycomed Pharma, Oslo, Norway) gradient according to standard procedures. Monocytes were
purified from PBMCs by magnetic cell sorting using CD14 microbeads (Miltenyi Biotech, Bergisch
Gladbach, Germany). Monocytes (>95% CD14+ cells) were cultured at 0.5 × 106 cells/mL for 4–7 days
in RPMI media supplemented with 10% fetal bovine serum (FBS, Gibco; complete medium), containing
1000 U/mL GM-CSF or 10 ng/mL M-CSF (ImmunoTools GmbH, Friesoythe, Germany) to generate
GM-MΦ and M-MΦ monocyte-derived macrophages, respectively. Cytokines were added every
two days. When necessary, the MMP-12 specific inhibitor MMP-408 (10 µg/mL) was added to the
culture media.
4.2. Endothelial Cell Culture
Human umbilical vein-derived endothelial cells (HUVECs) were purchased from Lonza (Basel,
Switzerland) and used at early passages [47]. HUVECs were grown on 0.2% gelatin (Sigma-Aldrich,
St. Louis, MO, USA) pre-coated plates in endothelial basal medium (EBM2) supplemented with 10%
heat-inactivated FBS and EGM2 SingleQuots (EBM2/EGM2 medium; Lonza, Basel, Switzerland) unless
otherwise noted. When indicated, HUVECs were cultured in the presence of MΦ conditioned media.
To this end, primary cultures of HUVECs were grown in EBM2/EGM2 medium until 90% confluency.
After removing the media, cells were washed twice with PBS. Supernatants of previously polarized
GM-MΦ or M-MΦ (6 days) were centrifuged, added to the HUVEC monolayers, and then incubated
for 24 h. The resulting culture supernatants were centrifuged and stored for further analysis.
4.3. Tube Formation and wound Healing Assays
In vitro tubulogenesis and wound healing assays were performed as previously described [47].
Briefly, for tube formation assays, HUVECs were seeded on 24-well plates previously covered with
120 µL standard Matrigel (BD Bioscience, San Jose, CA, USA) diluted 1:1 in serum-free RPMI medium
or MΦ supernatants for 3 h and 6 h, as indicated. Images were taken with an Olympus digital
camera, and quantification of closed tubes (tubular structures/microscopic field) was performed using
Fiji-ImageJ software. In vitro scratch wounds were created by scraping confluent HUVEC monolayers
in 24-well plates with a sterile pipette tip. Fresh EBM2 medium supplemented with 2% FBS and EGM2
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SingleQuots diluted 1:1 with MΦ supernatants was added, and samples were incubated for up to 10 h.
Endothelial cell migration into the denuded area was monitored at different times and recorded at 8 h
post-wound. The ImageJ program [70] was used to quantify the wound healing process.
4.4. Quantitative RT-PCR
Total RNA was extracted using an RNeasy kit (Qiagen, Hilden, Germany), retrotranscribed, and
amplified in triplicates. Oligonucleotides for selected human and mouse genes (ENG, MMP-1, MMP-2,
MMP-7, MMP-9, MMP-12, MMP-14, MMP-15, MMP-17, MMP-19, MMP-23B, MMP-25, MMP-28,
Mmp-12) were designed according to the Universal ProbeLibrary system (Roche Diagnostics, Mannheim,
Germany) for quantitative real-time PCR (qRT-PCR). Results were expressed relative to the expression
level of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). For siRNA-transfected MΦ, total
RNA was extracted using the NucleoSpin RNA/Protein kit (Macherey-Nagel, Düren, Germany),
retrotranscribed, and amplified using the Universal Human Probe Library (Roche Diagnostics,
Mannheim, Germany). Assays were made in triplicate, and results were normalized according
to the expression levels of TATA-binding protein (TBP) and hypoxanthine phosphoribosyltransferase 1
(HPTR1) genes.
4.5. Immunodetection Assays
Western blot analysis was performed as described previously [71]. Immunodetection was carried
out by probing the membrane with a mouse monoclonal antibody (mAb) against human endoglin
(P4A4; Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA, USA) or the V5
artificial epitope (Sigma-Aldrich, Saint Louis, MO, USA) overnight at 4 ◦C, followed by incubation
with the proper horseradish peroxidase-conjugated secondary antibody. Culture supernatants from
HUVECs, GM-MΦ, M-MΦ, or COS-7-lipofected cells were collected and centrifuged at 11,000× g for
10 min to remove cellular debris. The presence of human sEng or MMP-12 in culture supernatants was
analyzed using the Endoglin/CD105 Quantikine (DNDG00, R&D Systems, Minneapolis, MN, USA) or
MMP-12 (LS-F24617, LSBio, Seattle, WA, USA) ELISA kit, respectively, according to the manufacturers’
instructions. For immunofluorescence flow cytometry analysis, cells were collected, centrifuged, and
washed twice with PBS at 4 ◦C. After blocking with 2% human AB+ serum in PBS for 30 min, cells
were incubated with the mouse mAb anti-endoglin (P4A4) or a nonspecific (isotype-matched) antibody
(negative control), followed by incubation with Alexa Fluor 488 goat anti-mouse antibodies (Invitrogen,
Waltham, MA, USA). The samples were analyzed in an EPICS Coulter XL flow cytometer.
4.6. Recombinant MMP-12 Activity
Recombinant human MMP-12 (R&D Systems, Minneapolis, MN, USA) activity was determined
with a quenched fluorogenic peptide Mca-PLGL-Dpa-AR-NH2 (R&D Systems, Minneapolis, MN,
USA), as previously described [57]. Briefly, MMP-12 was activated by incubation with an assay buffer
(50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% Brij-35; pH 7.5) at 37 ◦C for 30 h. The fluorescence
intensity was measured with a Varioskan flash spectral scanning multimode reader (Thermo Scientific,
Waltham, MA, USA). When necessary, a mixture of 0.4 ng/mL of activated rhMMP-12 with 6 µM of
fluorogenic peptide was incubated with 30 µM endoglin peptides or the MMP-12 inhibitor MMP-408.
Endoglin-related peptides P583 (TSKGLVLP), P447 (SLSFQLGLYL), and P230 (GPRTVTVK) with
N-terminal acetylation and C-terminal amidation [57] were synthesized and purified to >90% purity
(Biomedal SL, Sevilla, Spain).
4.7. Generation of the MMP-12 Expression Vector
To generate the recombinant vector, GM-MΦ mRNA was retrotranscribed using the
iScript complementary DNA synthesis kit (Bio-Rad, Hercules, CA, USA), followed by
amplification by PCR using a high fidelity Taq polymerase (5 Prime) with specific primers
for human MMP-12 (Fw: 5’-ATG-CGG-TAC-CAT-GGG-GAA-GTT-TCT-TCTAAT-A-3’; and Rv:
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5’-ATG-CCT-CGA-GCT-AAC-AAC-CAAACC-AGC-TAT-TGC-TTT-3’). “TA cloning” was performed
in the pcDNA3.1/V5-His TOPO vector according to manufacturer’s instructions (TA Expression Kit,
Invitrogen, Waltham, MA, USA). Reliability of the resulting construct (pcDNA3.1-MMP-12) was
checked by enzymatic digestion (BamHI-XhoI) and sequencing (Secugen, Madrid, Spain).
4.8. Transient Transfection Assays
For transient transfection studies the monkey kidney, the COS-7 cell line was grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% FBS. COS-7 cells were transiently transfected
with expression vectors pcDNA3.1-MMP-12 and pDisplay-ENG [72], encoding human MMP-12 and
endoglin, respectively. Control transfections with pDisplay empty vector (Invitrogen) or GFP vector
(Lonza, Basel, Switzerland) were also included. Transfection experiments were performed with
Lipofectamine LTX (Invitrogen) according to the manufacturer’s instructions. After 48 h, culture
supernatants were collected and the cells were lysed in lysis buffer (10 mM Tris-HCl pH 8.0, 150 mM
NaCl, 1% NP-40, and a cocktail of protease and phosphatase inhibitors) for later ELISA, western blot,
and zymography analyses. For MMP-12 silencing, GM-MΦ (1 × 106 cells/mL) were transfected with a
pool of MMP-12-specific small interfering RNA (s92, si93, and si94; 50 nM each; Sigma) using Hiperfect
(#301705, Qiagen, Hilden, Germany). As a negative control, cells were transfected with a nonspecific
small interfering RNA control (siControl; Life Technologies, Carlsbad, CA, USA). After transfection,
cells were cultured for the indicated times in RPMI 1640 supplemented with 10% FBS and subjected to
mRNA and protein analysis.
4.9. Casein Zymography
SDS-polyacrilamide gels (12%) were co-polymerized with 0.5 mg/mL bovine β-casein (Sigma).
After pre-running the gels, samples (cell culture supernatants) in Laemmli buffer 1× without reducing
agents were loaded without boiling and electrophoresed at 100 V. SDS was removed after the run
by washing the gel twice with 50 mM Tris-HCl (pH 7.5) and 2.5% Triton X-100 for 30 min and twice
more for 10 min with 50 mM Tris-HCl (pH 7.5). The gel was incubated overnight at 37 ◦C with 50 mM
Tris-HCl (pH 7.5), 0.15 M NaCl, 5 mM CaCl2, 2.5% Triton X-100, and 0.02% NaN3. The staining was
performed for 1 h at room temperature with 0.5% Coomassie Brilliant Blue R-250 in 10% acetic acid,
followed by destaining with 10% acetic acid until digestion bands were visible.
4.10. In Vivo Inflammatory Response and Inhibition of MMP-12 in a Mouse Model
Ten-week-old mice were injected (i.p.) with 1 mg/kg body weight of lipopolysaccharide (LPS;
from E. coli O111:B:4, Sigma-Aldrich, St. Louis, MO, USA) or PBS as a control condition. Three hours
before LPS injection, mice were orally gavaged with 150–200 µL of 0.5% methylcellulose, 2% Tween-80
(vehicle), or MMP-408 (30 mg/kg body weight; Merck-Millipore, Burlington, MA, USA). Vehicle or
MMP-408 gavage was repeated 24 h after i.p. injection with LPS. All animals were handled in strict
accordance with good animal practice as defined by the national animal welfare bodies (RD 1201/2005
BOE #252). The experimental design and all animal work were approved by our institutional Ethical
Committee for animal experiments. Mice were deeply anesthetized, and blood samples were obtained
by puncture of posterior vena cava. The blood was centrifuged for 15 min at 1000g to collect serum
samples. Levels of mouse sEng in serum were determined by DuoSet® ELISA Mouse Endoglin/CD105
Immunoassay (R&D Systems, Minneapolis, MN, USA).
4.11. Statistical Analysis
All the experiments were performed with ≥3 replicates in each condition and repeated, at least,
three times with similar results. Statistical analyses were performed on GraphPad Prism 8 for Windows
(La Jolla, CA, USA). Statistical significance was calculated using the paired two-tailed Student t test or
by ANOVA for multiple comparison and Tukey’s test. Statistical data are presented either as mean
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± standard deviation (SD) or as mean ± standard error of the mean (SEM), as indicated. A value of
*p < 0.05 was considered significant; **p < 0.01; ***p < 0.001.
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FBS Fetal Bovine Serum
GM-CSF Granulocyte-Macrophage Colony-Stimulating Factor
GM-MΦ GM-CSF monocyte-derived macrophage
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M-MΦ M-CSF monocyte-derived macrophage
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